Market Overview:
The global diabetic neuropathic pain drug market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The market was valued at US$ 2,848.0 Mn in 2017 and is projected to reach US$ 4,711.4 Mn by 2030. The growth of the global diabetic neuropathic pain drug market can be attributed to factors such as rising prevalence of diabetes, increasing awareness about available treatment options for diabetic neuropathic pain, and growing demand for novel therapies for the treatment of chronic diseases such as diabetes mellitus (DM). Based on type, the global diabetic neuropathic pain drug market has been segmented into AZD-5213, clonidine hydrochloride, duloxetine hydrochloride DR (Cymbalta), E-52862 (Sarizotan), filgrastim (Neupogen), GERPOOI (GRC-17536), GRC-17536 Others). Duloxetine hydrochloride DR is expected to account for a major share of the global diabetic neuropathic pain drug market in terms of revenue in 2018 owing to its high efficacy and safety profile compared with other drugs available in this category.
Product Definition:
A diabetic neuropathic pain drug is a medication that is used to treat nerve damage caused by diabetes. This type of medication can help to relieve the pain and discomfort that is often associated with this condition.
AZD-5213:
Neuropathic pain is a type of chronic pain that occurs as a result of damage to the nerves that carry information about the body's organs and tissues. Neuropathic pain often remains undiagnosed owing to underdiagnosis and lack of awareness among patients. The drug, called Azelis (N-Acetyl-L-Tyrosine) has been proven to be more effective than any other drug in treating diabetic neuropathic pain.
Clonidine Hydrochloride:
Clonidine hydrochloride is a prescription drug used to treat symptoms of withdrawal from drugs that cause drowsiness, such as opiates and benzodiazepines. It works by decreasing the activity in the part of the brain that controls pain. Clonidine is an alpha-2 adrenergic receptor agonist and has been shown to be effective in treating diabetic neuropathic pain when added to long-acting opioids.
Application Insights:
Based on application, the global diabetic neuropathic pain drug market is segmented into hospital, clinic or office-based settings and others such as home care, emergency department (ED), and other medical facilities. Hospital-based settings held the largest share in 2017 owing to factors such as a high prevalence of diabetes coupled with rising awareness about NPDR drugs.
The ED segment is expected to witness lucrative growth over the forecast period due to increasing incidence of acute pain disorders among patients suffering from diabetes. In addition, growing initiatives by manufacturers for developing nonopioid analgesic alternatives for treating NPDR are expected to drive demand over the forecast period. For instance, in January 2018 Pfizer Inc., one of America's largest pharmaceutical companies announced that they are working with Otsuka Pharmaceutical Co., Ltd.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing prevalence of diabetes are some factors responsible for its growth. According to the CDC National Center for Health Statistics (NCHS), in 2016 about 29.1 million people were living with diabetes in U.S.
Asia Pacific region is anticipated to witness lucrative CAGR over the forecast period owing high unmet clinical needs coupled with rapidly improving healthcare infrastructure.
In addition, growing awareness regarding treatment options through various programs organized by manufacturers & government agencies such as WHO & FDA approval for new products launch are also driving regional market growth for instance; Sun Pharma.
Growth Factors:
- Increasing prevalence of diabetes: The global prevalence of diabetes is increasing at an alarming rate. This is expected to drive the demand for diabetic neuropathic pain drugs in the coming years.
- Growing awareness about diabetic neuropathy: There is a growing awareness among people about diabetic neuropathy and its associated risks. This is likely to boost the demand for effective treatments for this condition in the near future.
- Rising R&D expenditure by pharmaceutical companies: Pharmaceutical companies are investing heavily in R&D to develop novel therapies for treating diabetic neuropathic pain. This is likely to result in the launch of new and better drugs in this market over the next few years.
- Technological advancements: The development of novel technologies such as gene therapy, stem cell therapy, and nanotechnology has opened up new avenues for treatment of diabetic neuropathic pain drug market .This is expected to spur growth prospects for this market over the next few years.. 5) Emerging markets offer untapped potential: The emerging markets offer a huge potential for growth owing to their large population base and rising incidence of diabetes
Scope Of The Report
Report Attributes
Report Details
Report Title
Diabetic Neuropathic Pain Drug Market Research Report
By Type
AZD-5213, Clonidine Hydrochloride, Duloxetine Hydrochloride DR, E-52862, Filgrastim, GERPOOI, GRC-17536, Others
By Application
Clinic, Hospital, Others
By Companies
Astellas Pharma Inc., AstraZeneca Plc, BioDelivery Sciences International, Inc., Boehringer Ingelheim GmbH, Daiichi Sankyo Company, Limited, Dong-A Socio Group, Eli Lilly and Company, Glenmark Pharmaceuticals Ltd., Hydra Biosciences, Inc., Immune Pharmaceuticals Inc., Laboratorios Del Dr. Esteve S.A., Lohocla Research Corporation, Mertiva AB, Novaremed, Pharmaleads, RAPID Pharmaceuticals AG, Relmada Therapeutics, Inc., Sphaera Pharma Pvt. Ltd., Theravasc, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
157
Number of Tables & Figures
110
Customization Available
Yes, the report can be customized as per your need.
Global Diabetic Neuropathic Pain Drug Market Report Segments:
The global Diabetic Neuropathic Pain Drug market is segmented on the basis of:
Types
AZD-5213, Clonidine Hydrochloride, Duloxetine Hydrochloride DR, E-52862, Filgrastim, GERPOOI, GRC-17536, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Astellas Pharma Inc.
- AstraZeneca Plc
- BioDelivery Sciences International, Inc.
- Boehringer Ingelheim GmbH
- Daiichi Sankyo Company, Limited
- Dong-A Socio Group
- Eli Lilly and Company
- Glenmark Pharmaceuticals Ltd.
- Hydra Biosciences, Inc.
- Immune Pharmaceuticals Inc.
- Laboratorios Del Dr. Esteve S.A.
- Lohocla Research Corporation
- Mertiva AB
- Novaremed
- Pharmaleads
- RAPID Pharmaceuticals AG
- Relmada Therapeutics, Inc.
- Sphaera Pharma Pvt. Ltd.
- Theravasc, Inc.
Highlights of The Diabetic Neuropathic Pain Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- AZD-5213
- Clonidine Hydrochloride
- Duloxetine Hydrochloride DR
- E-52862
- Filgrastim
- GERPOOI
- GRC-17536
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Diabetic Neuropathic Pain Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A diabetic neuropathic pain drug is a medication that is used to treat diabetic neuropathy.
Some of the major companies in the diabetic neuropathic pain drug market are Astellas Pharma Inc., AstraZeneca Plc, BioDelivery Sciences International, Inc., Boehringer Ingelheim GmbH, Daiichi Sankyo Company, Limited, Dong-A Socio Group, Eli Lilly and Company, Glenmark Pharmaceuticals Ltd., Hydra Biosciences, Inc., Immune Pharmaceuticals Inc., Laboratorios Del Dr. Esteve S.A., Lohocla Research Corporation, Mertiva AB, Novaremed, Pharmaleads, RAPID Pharmaceuticals AG, Relmada Therapeutics, Inc., Sphaera Pharma Pvt. Ltd., Theravasc, Inc..
The diabetic neuropathic pain drug market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Diabetic Neuropathic Pain Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Diabetic Neuropathic Pain Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Diabetic Neuropathic Pain Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Diabetic Neuropathic Pain Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Diabetic Neuropathic Pain Drug Market Size & Forecast, 2018-2028
4.5.1 Diabetic Neuropathic Pain Drug Market Size and Y-o-Y Growth
4.5.2 Diabetic Neuropathic Pain Drug Market Absolute $ Opportunity
Chapter 5 Global Diabetic Neuropathic Pain Drug Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Diabetic Neuropathic Pain Drug Market Size Forecast by Type
5.2.1 AZD-5213
5.2.2 Clonidine Hydrochloride
5.2.3 Duloxetine Hydrochloride DR
5.2.4 E-52862
5.2.5 Filgrastim
5.2.6 GERPOOI
5.2.7 GRC-17536
5.2.8 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Diabetic Neuropathic Pain Drug Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Diabetic Neuropathic Pain Drug Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Hospital
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Diabetic Neuropathic Pain Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Diabetic Neuropathic Pain Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Diabetic Neuropathic Pain Drug Analysis and Forecast
9.1 Introduction
9.2 North America Diabetic Neuropathic Pain Drug Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Diabetic Neuropathic Pain Drug Market Size Forecast by Type
9.6.1 AZD-5213
9.6.2 Clonidine Hydrochloride
9.6.3 Duloxetine Hydrochloride DR
9.6.4 E-52862
9.6.5 Filgrastim
9.6.6 GERPOOI
9.6.7 GRC-17536
9.6.8 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Diabetic Neuropathic Pain Drug Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Hospital
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Diabetic Neuropathic Pain Drug Analysis and Forecast
10.1 Introduction
10.2 Europe Diabetic Neuropathic Pain Drug Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Diabetic Neuropathic Pain Drug Market Size Forecast by Type
10.6.1 AZD-5213
10.6.2 Clonidine Hydrochloride
10.6.3 Duloxetine Hydrochloride DR
10.6.4 E-52862
10.6.5 Filgrastim
10.6.6 GERPOOI
10.6.7 GRC-17536
10.6.8 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Diabetic Neuropathic Pain Drug Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Hospital
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Diabetic Neuropathic Pain Drug Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Diabetic Neuropathic Pain Drug Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Diabetic Neuropathic Pain Drug Market Size Forecast by Type
11.6.1 AZD-5213
11.6.2 Clonidine Hydrochloride
11.6.3 Duloxetine Hydrochloride DR
11.6.4 E-52862
11.6.5 Filgrastim
11.6.6 GERPOOI
11.6.7 GRC-17536
11.6.8 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Diabetic Neuropathic Pain Drug Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Hospital
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Diabetic Neuropathic Pain Drug Analysis and Forecast
12.1 Introduction
12.2 Latin America Diabetic Neuropathic Pain Drug Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Diabetic Neuropathic Pain Drug Market Size Forecast by Type
12.6.1 AZD-5213
12.6.2 Clonidine Hydrochloride
12.6.3 Duloxetine Hydrochloride DR
12.6.4 E-52862
12.6.5 Filgrastim
12.6.6 GERPOOI
12.6.7 GRC-17536
12.6.8 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Diabetic Neuropathic Pain Drug Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Hospital
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Diabetic Neuropathic Pain Drug Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Diabetic Neuropathic Pain Drug Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Diabetic Neuropathic Pain Drug Market Size Forecast by Type
13.6.1 AZD-5213
13.6.2 Clonidine Hydrochloride
13.6.3 Duloxetine Hydrochloride DR
13.6.4 E-52862
13.6.5 Filgrastim
13.6.6 GERPOOI
13.6.7 GRC-17536
13.6.8 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Diabetic Neuropathic Pain Drug Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Hospital
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Diabetic Neuropathic Pain Drug Market: Competitive Dashboard
14.2 Global Diabetic Neuropathic Pain Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Astellas Pharma Inc.
14.3.2 AstraZeneca Plc
14.3.3 BioDelivery Sciences International, Inc.
14.3.4 Boehringer Ingelheim GmbH
14.3.5 Daiichi Sankyo Company, Limited
14.3.6 Dong-A Socio Group
14.3.7 Eli Lilly and Company
14.3.8 Glenmark Pharmaceuticals Ltd.
14.3.9 Hydra Biosciences, Inc.
14.3.10 Immune Pharmaceuticals Inc.
14.3.11 Laboratorios Del Dr. Esteve S.A.
14.3.12 Lohocla Research Corporation
14.3.13 Mertiva AB
14.3.14 Novaremed
14.3.15 Pharmaleads
14.3.16 RAPID Pharmaceuticals AG
14.3.17 Relmada Therapeutics, Inc.
14.3.18 Sphaera Pharma Pvt. Ltd.
14.3.19 Theravasc, Inc.
